July 23, 2010
Securities and Exchange Commission
Division of Corporate Finance
100 F St., N.E.
Washington, D.C. 20549
| Attn: | Jeffrey Riedler |
| John L. Krug |
| Re: | Trius Therapeutics, Inc. (the “Company”) |
| Registration Statement on Form S-1 |
| (File No. 333-162945) |
Ladies and Gentlemen:
In connection with the proposed offering of the above-captioned securities, we wish to advise you that we, as a representative of the underwriters, hereby join with the Company’s request that the effective date of the above-captioned Registration Statement be accelerated so that the same will become effective on July 27, 2010 at 4:00 p.m., Eastern Standard Time or as soon as practicable thereafter.
The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:
| (i) | Date of preliminary prospectus: July 13, 2010 |
| (ii) | Approximate dates of distribution: July 13, 2010 to July 22, 2010 |
| (iii) | Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 4 |
| (iv) | Number of prospectuses so distributed: 6025 |
| (v) | Compliance with Rule 15c2-8 under the Securities Exchange Act of 1934: Included in Master Agreement Among Underwriters of Citigroup Global Markets Inc. |
| Very truly yours, |
/s/ Eric W. Wooley |
| Citigroup Global Markets Inc. |
| Eric W. Wooley |
| Director |
